Business Description
Pharma Equity Group A/S
ISIN : DK0061155009
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.14 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.78 | |||||
Debt-to-EBITDA | -1.23 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 71.8 | |||||
3-Year EPS without NRI Growth Rate | 67.8 | |||||
3-Year FCF Growth Rate | 63.6 | |||||
3-Year Book Growth Rate | -67.2 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 15.14 | |||||
9-Day RSI | 23.51 | |||||
14-Day RSI | 29.38 | |||||
6-1 Month Momentum % | -28.98 | |||||
12-1 Month Momentum % | -8.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.96 | |||||
Quick Ratio | 1.96 | |||||
Cash Ratio | 0.12 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -218 | |||||
Shareholder Yield % | -4.7 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -48.53 | |||||
ROA % | -29.75 | |||||
ROIC % | -32.49 | |||||
ROC (Joel Greenblatt) % | -57.8 | |||||
ROCE % | -48.06 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 6.99 | |||||
Price-to-Tangible-Book | 8.37 | |||||
EV-to-EBIT | -11.19 | |||||
EV-to-EBITDA | -11.54 | |||||
EV-to-FCF | -19.87 | |||||
Price-to-Net-Current-Asset-Value | 12.55 | |||||
Earnings Yield (Greenblatt) % | -8.95 | |||||
FCF Yield % | -6.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return %
Total Annual Return %
Pharma Equity Group A/S Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | |||
EPS (TTM) (kr) | -0.168 | ||
Beta | -0.31 | ||
Volatility % | 125.25 | ||
14-Day RSI | 29.38 | ||
14-Day ATR (kr) | 0.023849 | ||
20-Day SMA (kr) | 0.2956 | ||
12-1 Month Momentum % | -8.9 | ||
52-Week Range (kr) | 0.236 - 0.6 | ||
Shares Outstanding (Mil) | 1,022.95 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Pharma Equity Group A/S Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Pharma Equity Group A/S Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Pharma Equity Group A/S Frequently Asked Questions
What is Pharma Equity Group A/S(OCSE:PEG)'s stock price today?
When is next earnings date of Pharma Equity Group A/S(OCSE:PEG)?
Does Pharma Equity Group A/S(OCSE:PEG) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |